Catch up with the latest happenings at Terremoto.
Terremoto Biosciences announced that it received Fast Track Designation granted for TER-2013 in HR+/HER2- breast cancer with AKT/PI3K/PTEN-alterations following endocrine therapy and CDK4/6 inhibitor therapy
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer
/in 2026, Press Release/by eallisonTerremoto Biosciences announced that it received Fast Track Designation granted for TER-2013 in HR+/HER2- breast cancer with AKT/PI3K/PTEN-alterations following endocrine therapy and CDK4/6 inhibitor therapy
Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia
/in 2026, Press Release/by David AndersonTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round.
Terremoto Biosciences Appoints James Christensen, Ph.D., as President, Head of Research & Development
/in 2025, Press Release/by Jane ShankTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer
/in 2024, Press Release/by Jane ShankTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences Closes $175 Million Series B Financing
/in 2023, Press Release/by David AndersonTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines
/in 2022, Press Release/by eallisonTerremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.